

Takahiro Takase

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/521193/publications.pdf>

Version: 2024-02-01

9
papers

167
citations

1478505

6
h-index

1588992

8
g-index

9
all docs

9
docs citations

9
times ranked

280
citing authors

#	ARTICLE	IF	CITATIONS
1	Favorable effect of sodium-glucose cotransporter ² inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone. <i>Journal of Diabetes Investigation</i> , 2021, 12, 1272-1277.	2.4	28
2	Acromegaly Cases Exhibiting Increased Growth Hormone Levels during Oral Glucose Loading with Preadministration of Dipeptidyl Peptidase-4 Inhibitor. <i>Internal Medicine</i> , 2021, 60, 2375-2383.	0.7	1
3	Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type ² diabetes and osteopenia/osteoporosis. <i>Journal of Diabetes Investigation</i> , 2020, 12, 1293-1300.	2.4	3
4	Effects of <i>Palmaria palmata</i> on lipid metabolism and glycemic control in participants with hypercholesterolemia in a randomized double-blind placebo-controlled trial. <i>Phytotherapy Research</i> , 2020, 34, 2303-2312.	5.8	6
5	Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial. <i>Journal of Diabetes Investigation</i> , 2019, 10, 699-705.	2.4	26
6	Reduction in glucose fluctuations in elderly patients with type 2 diabetes using repaglinide: A randomized controlled trial of repaglinide vs sulfonylurea. <i>Journal of Diabetes Investigation</i> , 2019, 10, 367-374.	2.4	15
7	Factors with remission of fatty liver in patients with type 2 diabetes treated with ipragliflozin. <i>Endocrine Journal</i> , 2019, 66, 995-1000.	1.6	6
8	Effect of switching from pioglitazone to the sodium glucose co-transporter ² inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type 2 diabetes mellitus: An open-label, prospective, randomized, parallel-group comparison trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 710-714.	4.4	12
9	Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects. <i>Endocrine Journal</i> , 2017, 64, 363-367.	1.6	70